



1644

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In Re the Application of:

LAHN et al.

Serial No.: 09/826,319

Filed: April 3, 2001

Atty. File No.: 2879-80

For: "METHOD TO INHIBIT AIRWAY
HYPERRESPONSIVENESS USING
AEROSOLIZED T CELL
RECEPTOR ANTIBODIES"Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to Applicants' duty of disclosure under 37 CFR § 1.56, Applicants hereby submit this Supplemental Information Disclosure Statement with a copy of the documents identified on the enclosed PTO Form 1449, although Applicants do not admit that any of such documents, alone or in any combination, are considered to be material to patentability as defined in 37 CFR § 1.56(b). Moreover, the inclusion of these documents is not to be construed as an admission by Applicants that each such document is prior art as to the above-identified patent application.

I hereby certify that each item of information contained in this Supplemental Information Disclosure Statement was cited in the International Search Report in a counterpart international application not more than 3 months prior to the filing of this statement.

Respectfully submitted,

SHERIDAN ROSS P.C.

By: Angela Dallas

Angela K. Dallas

Registration No. 42,460
1560 Broadway, Suite 1200
Denver, CO 80202-5141
(303) 863-9700Date: October 31, 2002SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

P#9

CERTIFICATE OF MAILING	
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO THE COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231 ON <u>10/31/02</u>	
BY:	<u>Tyler Russell</u>
SHERIDAN ROSS P.C.	